Therapeutic options for drug induced liver injury: The efficacy of UDCA based on EBM

Japanese Journal of Gastroenterology

Volumn 100, Issue 6, 2003, Pages 659-666

  Matsuzaki, Yasushi ^a   Nishikawa, Kiyohiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLUTAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PARACETAMOL; PHENOBARBITAL; URSODEOXYCHOLIC ACID;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HUMAN; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; NONHUMAN; PROSTATE CANCER;

EID: 0037971034     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Marino G, Zimmerman HJ, Lewis JH: Management of drug-induced liver disease. Curr Gastroenterol Rep 2001; 3: 38-48
2. Chitturi S, Farrell GC: Drug-induced cholestasis. Semin Gastrointest Dis 2001; 12: 113-124
3. Bernstein D, Tripodi J: Fulminant hpatic failure. Crit Care Clin 1998; 14: 181-197
4. McClain CJ, Price S, Barve S, et al: Acetoaminophen hepatotoxicity: An update. Curr Gastroenterol Rep 1999; 1: 12-19
5. Matsuzaki Y: Colestimide: The efficacy of a novel anion-exchange resin in cholestatic disorders. J Gastroenterol Hepatol 2002; 17: 1133-1135
6. Beato M, Herrlich P, Schutz G: Steroid hormone receptors: many actors in search of a plot. Cell 1995; 83: 851-857
7. Mangelsdoff DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839
8. Baldwin AS Jr: Series introduction: the transcription factor NF-κB and human disease. J Clin Invest 2001; 107: 241-246
9. Gottlicher M, Heck S, Karin M: Transcriptional cross-talk, the second mode of steroid hormone action. J Mol Med 1998; 76: 480-489
10. Karin M: New twists in gene regulation by glucocorcicoid receptor: is DNA binding disoensable? Cell 1998; 93: 487-490
11. Tokyo Cooperative Gallstone Study Group: Efficacy and indication of ursodeoxycholic acid treatment for dissolving gallstones. A multicenter double blind trial. Gastroenterology 1980; 78: 542-548
12. Osuga T, Tanaka N, Matsuzaki Y, et al: Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig Dis Sci 1989: 34 (Suppl 12): 49-51
13. Poupon R, Chretien Y, Poupon RE, et al: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-836
14. Matsuzaki Y, Tanaka N, Osuga T, et al: Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 15-23
15. Oka H, Toda G, Ikeda Y, et al: A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn 1990; 25: 774-780
16. Poupon RE, Balkou B, Eschwege E, et al: A multi-center, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-1554
17. Lindor KD, Thermeau TM, Jorgensen RA, et al: Effects of ursodeoxycholic acid on survival on patients with primary biliary cirrhosis. Gastroenterology 1996; 1110: 1515-1518
18. Takikawa H, Yamanaka M, Miyake K, et al: Ursodeoxycholic acid therapy for chronic type C hepatitis: A multicenter, dose-finding trial. Curr Ther Res 1994; 55: 16-21
19. Galle PR, Theilmann L, Raedsch R, et al: Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12: 486-491
20. Tanaka H, Makino I, Miura T, et al: Ligand-independent activation of the glucocorticoid receptor by ursodeoxychoic acid. J Immunol 1996; 156: 1601-1996
21. Ikegami T, Matsuzaki Y, Shoda J, et al: The chemopreventive role of ursodeoxhycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998; 134: 129-139
22. Hirano F, Kobayashi A, Hirano Y, et al: Bile acids regulate RANTES gene expression through its cognate NF-κB binding sites. Biochem Biophys Res Commun 2001; 288: 1095-1101
23. Miyishi H, Rust C, Guicciardi ME, et al: NF-κB is activated in cholestasis and functions to reduce liver injury. Am J Pathol 2001; 158: 967-975
24. Matsuzaki Y, Bouscarel B, Le M, et al: Effects of cholestasis on regulation of cAMP synthesis by glucagon and bile acids in isolated hepatocytes. Am J Physiol 1997; 273: G164-G174
25. Schliess F. Kurz AK. vom Dahl S. et al: Mitogen-acitivated protein kinase mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 1997; 13: 1306-1314
26. Kurz AK, Graf D. Schmitt M. et al: Tauroursodeoxycholate-induced choleresis involves p38 (MAPK) activation and translocation of bile salt export pump in rats. Gastroenterology 2001; 121: 407-419
27. Beuers U, Throckmorton DC. Anderson MS. et al: Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996; 110: 1553-1563
28. Beuers U. Bilzer M. Chittattau A. et al: Tauroursodexycholic acid inserts the apical conjugate export pump, Mrp2. into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanism in cholestatic rat liver. Hepatology 2001; 33: 1206-1216
29. Rosman AS, Frissora-Rodeo C, Marshall AT, et al: Cholestatic hepatitis following flutamide. Dig Dis Sci 1993; 38: 1756-1759
30. Moller S, Iversen P, Franzmann M: Flutamide-induced liver failure. J Hepatol 1990; 10: 346-349
31. McDonnell ND, Livingston RB: Severe reversible neutropenia following treatment of prostate cancer with flutamide. J Urol 1994; 151: 1353-1354
32. Fau D, Eugene D, Berson A. et al: Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994; 269:954-962
33. Cinognani C, Malavolti M, Morselli-Labate AM, et al: Flutamide-induced toxic hepatitis. Dig Dis Sci 1996; 41: 2219-2221
34. Shet MS, McPhaul M, Fisher CW. et al: Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Diposit 1997; 25: 1298-1303
35. Nava-Ocampo AA, Suster S, Muriel P: Effect of cholchicine and ursodeoxycholic acid on hepatocyte and erythrocyte membrane and liver histology in experimentally induced carbon tetrachlolide cirrhosis in rats. Eur J Clin Invest 1997; 27: 77-84
36. Rudi J. Schlenker T, Raedsch R, et al: Effect of ursodeoxycholic acid on biochemical parameters, hepatocyte proliferation and liver histology in galactosamine hepatitis in the rat. Res Exp Med 1995; 195: 309-315
37. Kojima M, Kamoi K, Ukimura O, et al: Clinical utility of ursodeoxycholic acid in preventing fluta-mide-induced hepatopathy in patients with prostate cancer: A preliminary study. Int J Urol 2002; 9: 42-46